Maeda reviews the development of Medical Affairs in Japan and the regulatory and governance events that accelerated its professionalisation. The article describes limited formal MA structures before the mid-2000s, the impact of research-integrity controversies, and subsequent guidance that strengthened separation of scientific and post-marketing evidence activities from sales.